Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Leuprorelin for Severe Polycystic Liver Disease
NCT05478083Phase 2Recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Jun 2022
- Primary completion
- Jun 2027
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of leuprolide in Polycystic liver disease (PLD), sponsored by University Medical Center Groningen. Started Jun 2022; status: recruiting.
02
Drugs
leuprolide
03
Conditions
Polycystic liver disease (PLD)
Beyond the preview
Go deeper on NCT05478083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05478083.